anti-gD-MMAE

**anti-gD-MMAE** is an antibody-drug conjugate (ADC) composed of an antibody targeting glycoprotein D (gD), typically found on the envelope of herpes simplex virus (HSV), chemically linked to the cytotoxic payload **monomethyl auristatin E (MMAE)**. MMAE is a highly potent antimitotic agent derived from dolastatins, which inhibits cell division by blocking tubulin polymerization. Within the ADC, the antibody component confers specificity by binding to cells expressing gD, facilitating internalization of the conjugate. The linker (commonly a protease-cleavable linker such as valine-citrulline) ensures MMAE is released inside the target cell—where it exerts its cytotoxic effects, leading to targeted cell death and minimizing off-target toxicity. anti-gD-MMAE is being developed primarily for the treatment of cancers with cells expressing the gD antigen or engineered to express it for potential oncolytic virotherapy or targeted cytotoxicity. The specific developer, precise indication, and clinical status require further confirmation in public databases, but its structure and mechanism are in line with other MMAE-conjugated ADCs[1][3][5][7][9].

Brand names

αgD-MMAE

Other names

αgD-MMAE